Prospective study on cirrhotic heart problems in adults and kids
Official title: Prospective Investigation of Cirrhotic Cardiomyopathy in Humans
Funded at Vanderbilt University Medical Center · NIH-11417934 · Data updated 2026-11-12
Aimed at understanding how cirrhosis affects heart function in people with liver disease, through careful heart tests and patient data.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | September 16, 2025 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $755,072 |
| NIH project number | 5R01HL181174-02 |
| Project ID | NIH-11417934 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults and children with cirrhosis who are evaluated for heart function.
✕Less likely to help
People without liver disease or without cardiomyopathy features may not directly benefit.
What this research studies
This project follows people with cirrhosis to see how common and serious cirrhotic cardiomyopathy is, using modern heart imaging and clinical data. It will look at which clinical factors are linked with CCM and whether bile acids play a role in causing heart problems. The study builds on a CCM consortium experience to perform larger, forward-looking analyses rather than just past records. Results could clarify risks for death, liver-related outcomes, and heart events, guiding future care. The work will be conducted at Vanderbilt University Medical Center with collaboration from a multidisciplinary team.
Why it matters
Potential benefit: If successful, it could improve how doctors screen for and manage heart problems in people with cirrhosis, potentially improving survival and quality of life.
How similar studies have gone: Prior studies suggest CCM is common but have been small; this project aims to confirm and extend findings in a larger, prospective way.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Izzy, Manhal Jaber — Vanderbilt University Medical Center
- Study coordinator: Izzy, Manhal Jaber
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.